文献速递急性肾损伤肾血管病与高血压

强化降压治疗对SPRINT试验中急性肾损伤事件的影响

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).
PubMed 文献 · Am J Kidney Dis · 2017-11-20

SPRINT试验纳入9361例≥50岁、有≥1个心血管病危险因素者,随机分至收缩压目标<120 mmHg(强化组)或<140 mmHg(标准组)。强化组急性肾损伤事件更频繁(3.8% vs 2.3%;HR 1.64;95%CI 1.30-2.10;P<0.001),但多数为轻度且肾功能完全恢复。

要点

  • 强化降压增加急性肾损伤风险,但多为轻度。
  • 多数急性肾损伤事件后肾功能完全或部分恢复。
  • 结果不适用于糖尿病或无心血管病危险因素者。

核心结论

  • 强化降压治疗导致急性肾损伤事件更频繁,但多数病例轻微且多数参与者肾功能完全恢复。

研究设计与样本

  • SPRINT试验为随机对照试验,纳入9361例50岁及以上、有1个及以上心血管病危险因素者,随机分至收缩压目标<120 mmHg(强化组)或<140 mmHg(标准组)。

主要发现

  • 强化组179例(3.8%)发生急性肾损伤事件,标准组109例(2.3%)(HR 1.64;95%CI 1.30-2.10;P<0.001)。
  • 288例急性肾损伤事件中,248例(86.1%)为单次事件。
  • 按改良KDIGO标准,强化组与标准组急性肾损伤分期:1期128例(58.5%)vs 81例(62.8%);2期42例(19.2%)vs 18例(14.0%);3期42例(19.2%)vs 25例(19.4%)(P=0.5)。
  • 在有足够数据的急性肾损伤事件中,强化组187例事件中169例(90.4%)完全或部分缓解、9例(4.8%)部分缓解;标准组99例事件中86例(86.9%)完全或部分缓解、4例(4.0%)部分缓解。

临床怎么用

  • 强化降压治疗时应监测急性肾损伤事件,但多数事件轻微且肾功能可恢复。

局限性

  • 试验结果不能推广至糖尿病患者或无心血管病危险因素的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events. STUDY DESIGN: Data for AKI resulting in or during hospitalization or emergency department visits were collected as part of the serious adverse events reporting process of the Systolic Blood Pressure Intervention Trial (SPRINT). SETTING & PARTICIPANTS: 9,361 participants 50 years or older with 1 or more risk factors for cardiovascular disease. INTERVENTIONS: Participants were randomly assigned to a systolic BP target of <120 (intensive arm) or <140mmHg (standard arm). OUTCOMES & MEASUREMENTS: Primary outcome was the number of adjudicated AKI events. Secondary outcomes included severity of AKI and degree of recovery of kidney function after an AKI event. Baseline creatinine concentration was defined as the most recent SPRINT outpatient creatinine value before the date of the AKI event. RESULTS: There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%; HR, 1.64; 95% CI, 1.30-2.10; P<0.001). Of 288 participants with an AKI event, 248 (86.1%) had a single AKI event during the trial. Based on modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria for severity of AKI, the number of AKI events in the intensive versus standard arm by KDIGO stage was 128 (58.5%) versus 81 (62.8%) for AKI stage 1, 42 (19.2%) versus 18 (14.0%) for AKI stage 2, and 42 (19.2%) versus 25 (19.4%) for AKI stage 3 (P=0.5). For participants with sufficient data, complete or partial resolution of AKI was seen for 169 (90.4%) and 9 (4.8%) of 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of 99 AKI events in the standard arm, respectively. LIMITATIONS: Trial results are not generalizable to patients with diabetes mellitus or without risk factors for cardiovascular disease. CONCLUSIONS: More intensive BP lowering resulted in more frequent episodes of AKI. Most cases were mild and most participants had complete recovery of kidney function. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT01206062.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Rocco MV, Sink KM, Lovato LC, et al. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2017. PMID: 29162340. doi:10.1053/j.ajkd.2017.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。